5o7p - Revision history

OCA at 19:10, 29 November 2023

2023-11-29T19:10:39Z

← Older revision		Revision as of 19:10, 29 November 2023
Line 1:		Line 1:

	==HER3 in complex with Fab MF3178==		==HER3 in complex with Fab MF3178==
	<StructureSection load='5o7p' size='340' side='right' caption='[[5o7p]], [[Resolution\|resolution]] 4.50Å' scene=''>		<StructureSection load='5o7p' size='340' side='right'caption='[[5o7p]], [[Resolution\|resolution]] 4.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5o7p]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O7P OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5O7P FirstGlance]. <br>		<table><tr><td colspan='2'>[[5o7p]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O7P OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5O7P FirstGlance]. <br>
	</td></tr><tr id='~~ligand~~'><td class="sblockLbl"><b>[[~~Ligand~~\|~~Ligands~~:]]</b></td><td class="sblockDat">~~<scene name='pdbligand=BMA:BETA-D~~-~~MANNOSE'>BMA</scene>~~, ~~<scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>~~</td></tr>		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 4.5Å</td></tr>
	<tr id='~~gene~~'><td class="sblockLbl"><b>[[~~Gene~~\|~~Gene~~:]]</b></td><td class="sblockDat"~~>ERBB3, HER3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&~~id=~~9606 HUMAN])</td~~><~~/tr>~~		<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	~~<tr id~~='~~activity'><td class~~=~~"sblockLbl"><b>Activity~~:~~</b~~></td><~~td class~~=~~"sblockDat"><span class~~=~~'plainlinks'>[http~~:~~//en.wikipedia.org/wiki/Receptor_protein~~-~~tyrosine_kinase Receptor protein~~-~~tyrosine kinase], with EC number [http://www.brenda~~-~~enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1]~~ </~~span~~></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5o7p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o7p OCA], [https://pdbe.org/5o7p PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5o7p RCSB], [https://www.ebi.ac.uk/pdbsum/5o7p PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5o7p ProSAT]</span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5o7p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o7p OCA], [~~http~~://pdbe.org/5o7p PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5o7p RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5o7p PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5o7p ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
	[~~[http~~://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:[~~http~~://omim.org/entry/607598 607598]]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.<ref>PMID:17701904</ref>		[https://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN] Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:[https://omim.org/entry/607598 607598]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.<ref>PMID:17701904</ref>
	== Function ==		== Function ==
	[~~[http~~://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Binds and is activated by neuregulins and NTAK.<ref>PMID:15358134</ref>		[https://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN] Binds and is activated by neuregulins and NTAK.<ref>PMID:15358134</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 26:		Line 25:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Human~~]]		[[Category: Homo sapiens]]
	[[Category: ~~Receptor protein-tyrosine kinase]]~~		[[Category: Large Structures]]
	~~[[Category: Gros, P~~]]		[[Category: De Nardis C]]
	[[Category: Nardis, C De]]		[[Category: Gros P]]
	[[Category: ~~Complex]]~~
	~~[[Category: Fab]]~~
	~~[[Category: Her3 ectodomain]]~~
	~~[[Category: Immune system~~]]

OCA at 07:37, 23 May 2018

2018-05-23T07:37:50Z

← Older revision		Revision as of 07:37, 23 May 2018
Line 3:		Line 3:
	<StructureSection load='5o7p' size='340' side='right' caption='[[5o7p]], [[Resolution\|resolution]] 4.50Å' scene=''>		<StructureSection load='5o7p' size='340' side='right' caption='[[5o7p]], [[Resolution\|resolution]] 4.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5o7p]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O7P OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5O7P FirstGlance]. <br>		<table><tr><td colspan='2'>[[5o7p]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O7P OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5O7P FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
			<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">ERBB3, HER3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5o7p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o7p OCA], [http://pdbe.org/5o7p PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5o7p RCSB], [http://www.ebi.ac.uk/pdbsum/5o7p PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5o7p ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5o7p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o7p OCA], [http://pdbe.org/5o7p PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5o7p RCSB], [http://www.ebi.ac.uk/pdbsum/5o7p PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5o7p ProSAT]</span></td></tr>
Line 12:		Line 13:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Binds and is activated by neuregulins and NTAK.<ref>PMID:15358134</ref>		[[http://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Binds and is activated by neuregulins and NTAK.<ref>PMID:15358134</ref>
			<div style="background-color:#fffaf0;">
			== Publication Abstract from PubMed ==
			HER2-driven cancers require phosphatidylinositide-3 kinase (PI3K)/Akt signaling through HER3 to promote tumor growth and survival. The therapeutic benefit of HER2-targeting agents, which depend on PI3K/Akt inhibition, can be overcome by hyperactivation of the heregulin (HRG)/HER3 pathway. Here we describe an unbiased phenotypic combinatorial screening approach to identify a bispecific immunoglobulin G1 (IgG1) antibody against HER2 and HER3. In tumor models resistant to HER2-targeting agents, the bispecific IgG1 potently inhibits the HRG/HER3 pathway and downstream PI3K/Akt signaling via a "dock & block" mechanism. This bispecific IgG1 is a potentially effective therapy for breast cancer and other tumors with hyperactivated HRG/HER3 signaling.

			Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.,Geuijen CAW, De Nardis C, Maussang D, Rovers E, Gallenne T, Hendriks LJA, Visser T, Nijhuis R, Logtenberg T, de Kruif J, Gros P, Throsby M Cancer Cell. 2018 May 14;33(5):922-936.e10. doi: 10.1016/j.ccell.2018.04.003. PMID:29763625<ref>PMID:29763625</ref>

			From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
			</div>
			<div class="pdbe-citations 5o7p" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
			[[Category: Human]]
	[[Category: Receptor protein-tyrosine kinase]]		[[Category: Receptor protein-tyrosine kinase]]
	[[Category: Gros, P]]		[[Category: Gros, P]]

OCA at 05:23, 16 May 2018

2018-05-16T05:23:36Z

← Older revision		Revision as of 05:23, 16 May 2018
Line 1:		Line 1:
	~~'''Unreleased structure'''~~

	~~The entry~~ 5o7p is ~~ON HOLD until Paper Publication~~		==HER3 in complex with Fab MF3178==
			<StructureSection load='5o7p' size='340' side='right' caption='[[5o7p]], [[Resolution\|resolution]] 4.50Å' scene=''>
	~~Authors~~: ~~De Nardis~~, C., ~~Gros~~, P.		== Structural highlights ==
			<table><tr><td colspan='2'>[[5o7p]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O7P OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5O7P FirstGlance]. <br>
	~~Description~~: ~~HER3~~ in ~~complex~~ with ~~Fab MF3178~~		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	[[~~Category~~: ~~Unreleased Structures~~]]		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Receptor_protein-tyrosine_kinase Receptor protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 2.7.10.1] </span></td></tr>
	[[Category: ~~De Nardis, C~~]]		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5o7p FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o7p OCA], [http://pdbe.org/5o7p PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5o7p RCSB], [http://www.ebi.ac.uk/pdbsum/5o7p PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5o7p ProSAT]</span></td></tr>
			</table>
			== Disease ==
			[[http://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Defects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:[http://omim.org/entry/607598 607598]]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.<ref>PMID:17701904</ref>
			== Function ==
			[[http://www.uniprot.org/uniprot/ERBB3_HUMAN ERBB3_HUMAN]] Binds and is activated by neuregulins and NTAK.<ref>PMID:15358134</ref>
			== References ==
			<references/>
			__TOC__
			</StructureSection>
			[[Category: Receptor protein-tyrosine kinase]]
	[[Category: Gros, P]]		[[Category: Gros, P]]
			[[Category: Nardis, C De]]
			[[Category: Complex]]
			[[Category: Fab]]
			[[Category: Her3 ectodomain]]
			[[Category: Immune system]]

OCA: Protected "5o7p" [edit=sysop:move=sysop]

2017-09-27T12:07:12Z

Protected "5o7p" [edit=sysop:move=sysop]

← Older revision	Revision as of 12:07, 27 September 2017
(No difference)

OCA: New page: '''Unreleased structure''' The entry 5o7p is ON HOLD until Paper Publication Authors: De Nardis, C., Gros, P. Description: HER3 in complex with Fab MF3178 [[Category: Unreleased Struct...

2017-09-27T12:07:11Z

New page: '''Unreleased structure''' The entry 5o7p is ON HOLD until Paper Publication Authors: De Nardis, C., Gros, P. Description: HER3 in complex with Fab MF3178 [[Category: Unreleased Struct...

New page

'''Unreleased structure'''

The entry 5o7p is ON HOLD until Paper Publication

Authors: De Nardis, C., Gros, P.

Description: HER3 in complex with Fab MF3178
[[Category: Unreleased Structures]]
[[Category: De Nardis, C]]
[[Category: Gros, P]]